DONGWHA PHARM.CO.,LTD: debt-to-equity, ROE and more
KOSPI, Legal name DONGWHA PHARM.CO.,LTD
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 60.0%
- Equity ratio
- 62.5%
- ROE
- 1.0%
- Op. margin
- 0.1%
- Rev. growth
- 6.8%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩65 | 20.7% |
| 2024 | ₩180 | 89.7% |
| 2023 | ₩180 | 18.2% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 24.3% | 80.4% | 5.4% | 7.7% | n/a |
| FY2022 consolidated | 21.8% | 82.1% | 5.7% | 8.8% | 16.2% |
| FY2023 consolidated | 38.8% | 72.0% | 6.9% | 5.2% | 6.1% |
| FY2024 consolidated | 54.3% | 64.8% | 0.5% | 2.9% | 28.7% |
| FY2025 consolidated | 60.0% | 62.5% | 1.0% | 0.1% | 6.8% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩293.0B | ₩340.4B | ₩361.1B | ₩464.9B | ₩496.4B |
| Operating profit | ₩22.5B | ₩29.9B | ₩18.8B | ₩13.4B | ₩256.8M |
| Pre-tax income | ₩26.5B | ₩23.1B | ₩37.0B | ₩6.9B | ₩6.0B |
| Net income | ₩19.6B | ₩21.6B | ₩28.2B | ₩2.1B | ₩3.8B |
| Total assets | ₩447.8B | ₩461.1B | ₩565.0B | ₩619.6B | ₩642.2B |
| Total liabilities | ₩87.7B | ₩82.5B | ₩157.9B | ₩218.0B | ₩240.7B |
| Total equity | ₩360.1B | ₩378.7B | ₩407.1B | ₩401.7B | ₩401.4B |
| Paid-in capital | ₩27.9B | ₩27.9B | ₩27.9B | ₩27.9B | ₩27.9B |
| Debt/equity (source value) | 24.3% | 21.8% | 38.8% | 54.3% | 60.0% |
Company outline (FSC)
- Market
- KOSPI
- Fiscal year end
- Dec
- Founded
- 1897-09-25
- Listed
- 76/03/24
- Employees
- 838
- Auditor
- 한울회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1101110043870
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 동화약품Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.